Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 7;8(10):1640.
doi: 10.3390/jcm8101640.

Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach

Angel L Montejo  1   2 , Nieves Prieto  3   4 , Rubén de Alarcón  5 , Nerea Casado-Espada  6 , Javier de la Iglesia  7 , Laura Montejo  8
Affiliations
Review

Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach

Angel L Montejo et al. J Clin Med. .

Abstract

Major depressive disorder is a serious mental disorder in which treatment with antidepressant medication is often associated with sexual dysfunction (SD). Given its intimate nature, treatment emergent sexual dysfunction (TESD) has a low rate of spontaneous reports by patients, and this side effect therefore remains underestimated in clinical practice and in technical data sheets for antidepressants. Moreover, the issue of TESD is rarely routinely approached by clinicians in daily praxis. TESD is a determinant for tolerability, since this dysfunction often leads to a state of patient distress (or the distress of their partner) in the sexually active population, which is one of the most frequent reasons for lack of adherence and treatment drop-outs in antidepressant use. There is a delicate balance between prescribing an effective drug that improves depressive symptomatology and also has a minimum impact on sexuality. In this paper, we detail some management strategies for TESD from a clinical perspective, ranging from prevention (carefully choosing an antidepressant with a low rate of TESD) to possible pharmacological interventions aimed at improving patients' tolerability when TESD is present. The suggested recommendations include the following: for low sexual desire, switching to a non-serotoninergic drug, lowering the dose, or associating bupropion or aripiprazole; for unwanted orgasm delayal or anorgasmia, dose reduction, "weekend holiday", or switching to a non-serotoninergic drug or fluvoxamine; for erectile dysfunction, switching to a non-serotoninergic drug or the addition of an antidote such as phosphodiesterase 5 inhibitors (PD5-I); and for lubrication difficulties, switching to a non-serotoninergic drug, dose reduction, or using vaginal lubricants. A psychoeducational and psychotherapeutic approach should always be considered in cases with poorly tolerated sexual dysfunction.

Keywords: TESD; anorgasmia; antidepressant; erectile dysfunction; management strategies; orgasm retardation; sexual dysfunction; treatment.

PubMed Disclaimer

Conflict of interest statement

A.L. Montejo received consultancy fees and honoraria/research grants in the last five years from Boehringer Ingelheim, Forum Pharmaceuticals, Rovi, Servier, Lundbeck, Otsuka, Janssen Cilag, Pfizer, Roche, Instituto de Salud Carlos III, and Junta de Castilla y León. N. Prieto has received consultancy fees and honoraria/research grants in the last five years from Boehringer Ingelheim, Lundbeck, Otsuka, Roche and Janssen Cilag. The other authors declare no conflicts of interest.

References

    1. FDA Selective Serotonin Reuptake Inhibitors (SSRIs) Information. [(accessed on 22 May 2019)]; Available online: https://www.fda.gov/drugs/information-drug-class/selective-serotonin-reu....
    1. Montejo-González A.L., Llorca G., Izquierdo J.A., Ledesma A., Bousoño M., Calcedo A., Carrasco J.L., Ciudad J., Daniel E., De la Gandara J., et al. SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J. Sex Marital Ther. 1997;23:176–194. doi: 10.1080/00926239708403923. - DOI - PubMed
    1. Serretti A., Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. J. Clin. Psychopharmacol. 2009;29:259–266. doi: 10.1097/JCP.0b013e3181a5233f. - DOI - PubMed
    1. Williams V.S.L., Edin H.M., Hogue S.L., Fehnel S.E., Baldwin D.S. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: Replication in a cross-sectional patient survey. J. Psychopharmacol. (Oxf.) 2010;24:489–496. doi: 10.1177/0269881109102779. - DOI - PubMed
    1. Reichenpfader U., Gartlehner G., Morgan L.C., Greenblatt A., Nussbaumer B., Hansen R.A., Van Noord M., Lux L., Gaynes B.N. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: Results from a systematic review with network meta-analysis. Drug Saf. 2014;37:19–31. doi: 10.1007/s40264-013-0129-4. - DOI - PubMed

LinkOut - more resources